2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersWhat’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment
Gazzola MG, Maclean E, Beitel M, Carmichael ID, Cammack KM, Eggert KF, Roehrich T, Madden LM, Jegede O, Zheng X, Bergman E, Barry DT. What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment. Journal Of General Internal Medicine 2022, 38: 653-660. PMID: 36163526, PMCID: PMC9971370, DOI: 10.1007/s11606-022-07813-w.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance use disordersMethadone treatmentUse disordersOutpatient methadone treatment programMethadone treatment programsPresenting problemPreferences of patientsTerminology preferencesSubstance-dependent personsCross-sectional surveyAdult patientsMean ageUnivariate analysisMain MeasuresParticipantsPatientsTreatment programKey ResultsWeSubstance abuseSubstance useDisordersSignificant differencesTreatmentDemographic differencesAddiction counselorsPrimary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infection
2021
“A good mother”: Impact of motherhood identity on women's substance use and engagement in treatment across the lifespan
Adams ZM, Ginapp CM, Price CR, Qin Y, Madden LM, Yonkers K, Meyer JP. “A good mother”: Impact of motherhood identity on women's substance use and engagement in treatment across the lifespan. Journal Of Substance Use And Addiction Treatment 2021, 130: 108474. PMID: 34118710, PMCID: PMC8478714, DOI: 10.1016/j.jsat.2021.108474.Peer-Reviewed Original ResearchConceptsSUD treatmentSubstance useSubstance use disorder treatmentSUD treatment programsUse disorder treatmentWomen's substance usePostpartum periodMost womenStudy staffIndependent authorsTreatment engagementDisorder treatmentTreatment programWomenSUD recoveryTreatmentMothersSpecific barriersChildrenResidential programsMiddle adulthoodFocus groupsCaretakersQualitative interviewsPregnancyProject MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial
Becker SJ, Murphy CM, Hartzler B, Rash CJ, Janssen T, Roosa M, Madden LM, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial. Addiction Science & Clinical Practice 2021, 16: 61. PMID: 34635178, PMCID: PMC8505014, DOI: 10.1186/s13722-021-00268-0.Peer-Reviewed Original ResearchConceptsOpioid treatment programsOpioid use disorderPatient outcomesTreatment programUse disordersContingency managementPutative mediatorsHybrid effectiveness-implementation trialOpioid-related problemsEffectiveness-implementation trialImplementation of CMImplementation outcomesUrgent public health needEvidence-based treatmentsUnit of randomizationPublic health emergencyPublic health needsOpioid abstinenceCM exposurePatient surveyEffective behavioral interventionsClinical trialsProvider surveySession audio recordingsHealth needs
2020
A qualitative investigation of addiction counselors' perceptions and experiences implementing an open-access model for treating opioid use disorder
Oberleitner LMS, Madden LM, Muthulingam D, Marcus R, Oberleitner DE, Beitel M, Gaeta M, Tamberelli JF, Barry DT. A qualitative investigation of addiction counselors' perceptions and experiences implementing an open-access model for treating opioid use disorder. Journal Of Substance Use And Addiction Treatment 2020, 121: 108191. PMID: 33357602, PMCID: PMC7770334, DOI: 10.1016/j.jsat.2020.108191.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentTreatment programOpioid treatment programsOpioid use disorderMaintenance treatmentTreatment optionsMethadone maintenanceUse disordersProspective patientsIndividual semi-structured interviewsCounselors' perceptionsTreatment organizationsInterdisciplinary teamCliniciansAddiction counselorsSemi-structured interviewsRapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal Of Substance Use And Addiction Treatment 2020, 121: 108164. PMID: 33191004, PMCID: PMC7769928, DOI: 10.1016/j.jsat.2020.108164.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyTake-home dosingInterim guidanceShort-term overall mortalityOpioid agonist treatment programPerson clinical encountersOAT deliveryAgonist therapyOverall mortalityCOVID-19 transmissionPatient dropoutOAT patientsNaloxone distributionOverdose educationClinical practiceClinic interactionsTreatment programClinical encountersPatientsCliniciansCOVID-19COVID-19 pandemicOverdosesDosingPrevious yearCorrelates of Homelessness Among Patients in Methadone Maintenance Treatment
Gaeta M, Beitel M, Oberleitner LMS, Oberleitner DE, Madden LM, Tamberelli JF, Barry DT. Correlates of Homelessness Among Patients in Methadone Maintenance Treatment. Medical Care 2020, 58: 1030-1034. PMID: 32925463, PMCID: PMC7668351, DOI: 10.1097/mlr.0000000000001414.Peer-Reviewed Original ResearchConceptsOpioid use disorderImportant public health roleLogistic regressionMethadone maintenance treatment programImportant public health issueTreatment-related correlatesCorrelates of homelessnessPercent of patientsMethadone maintenance treatmentFinal logistic regression modelMaintenance treatment programPublic health roleSymptoms of depressionBivariate logistic regressionPublic health issueLogistic regression modelsMaintenance treatmentUse disordersPatientsSignificant independent variablesHealth roleBivariate analysisTreatment programPast monthHigher symptomsCo-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2019
Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Collier E, Starr S, Madden LM, Haram E, Molfenter T. Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs. Journal Of Addiction Medicine 2019, 13: 28-34. PMID: 30095565, PMCID: PMC6349477, DOI: 10.1097/adm.0000000000000441.Peer-Reviewed Original ResearchConceptsOpioid use disorderTreatment programSubstance use disorder treatment programsImplementation of pharmacotherapyEffective pharmacological treatmentAvailability of buprenorphineTreatment organizationsDisorder treatment programsTablet naltrexoneInjectable naltrexoneAvailable medicationsPharmacological treatmentLifesaving treatmentPhysician outreachUse disordersPharmacotherapyMean numberTreatment slotsMedicationsNaltrexonePrescribersCurrent useResource needsPhysician recruitmentTreatment
2018
Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine
Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R, Altice FL. Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug And Alcohol Dependence 2018, 190: 82-88. PMID: 29990648, PMCID: PMC6292439, DOI: 10.1016/j.drugalcdep.2018.05.027.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid agonist treatmentOpioid-dependent peopleSubstance abuse treatment programsCross-sectional surveyAgonist therapyAgonist treatmentHIV preventionTreatment perceptionsTreatment efficacyOAT expansionStudy participantsTreatment programAddiction treatmentComposite measureSeveritySocial stigmaDrugsTreatmentStructural barriersBarrier severityParticipantsExperiences of Burnout among Drug Counselors in A Large Opioid Treatment Program: A Qualitative Investigation
Beitel M, Oberleitner L, Muthulingam D, Oberleitner D, Madden LM, Marcus R, Eller A, Bono MH, Barry DT. Experiences of Burnout among Drug Counselors in A Large Opioid Treatment Program: A Qualitative Investigation. Substance Abuse 2018, 39: 211-217. PMID: 29522381, DOI: 10.1080/08897077.2018.1449051.Peer-Reviewed Original ResearchConceptsExperience of burnoutDrug counselorsTreatment programJob-related demandsIndividual semi-structured interviewsWork engagementCounselor burnoutBurnoutCounselor feedbackPhysiological symptomsSemi-structured interviewsCounselorsQualitative investigationParticipantsPossible experienceSystem-level changesCounselor descriptionsExperienceProgram settingsOpioid treatment programsTreatment gapMultidisciplinary teamEngagementProgramTranscribed